A Phase 2 interventional study of Dostarlimab and CAPEOX in Neoplasms, Colon, sponsored by GlaxoSmithKline. Recruiting at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Colonic Neoplasms with a site in Belgium — 14 open to participants now, 22 under way, 7 of them phase 3. Colonic Neoplasms · Belgium.
Among the 64 studies in Colonic Neoplasms with a site in Belgium, this one is the 32nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 8 of the 21 other live ones, and was the 56th registered.
2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.
Browse Colonic Neoplasms studies →14 of the 64 studies in Colonic Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
Solstice Oncology, Inc. · Sites in Belgium, United States, Italy and 3 more countries
Ages 18+
Incyte Corporation · Sites in Belgium, United States, Argentina and 19 more countries
Ages 18+
Jules Bordet Institute · Sites in Belgium
Ages up to 100
Pfizer · Sites in Belgium, United States, Argentina and 14 more countries
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 24
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 75 across 1,710 interventional studies indexed under Colonic Neoplasms.
Median enrollment 283 across the 51 interventional studies, 100 across the 7 observational. Of the 35 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 4 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Colonic Neoplasms with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06567782GlaxoSmithKlineA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer | 2026-11-23 |
| NCT06792292ChirecArtificial Intelligence-Assisted Colonoscopy in Colorectal Cancer Screening in a General Hospital | 2026-12-31 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05877456University Hospital, GhentValidation of the Global Polypectomy Assessment Tool (GPAT) | 2027-03-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Colonic Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for "capecitabine + oxaliplatin") to check if using these two together works better than using just CAPEOX by itself. This treatment is given before any surgery takes place; a method referred to as "neoadjuvant therapy." . The aim is to see if this new approach can show early signs of effectiveness in treating participants with a specific type of colon cancer known as mismatch repair proficient/ microsatellite stable (MMRp/MSS), where the cells have normal repair systems and stable DNA sequences. This study will also look at specific signs in the blood and tumor to see if they can help predict how well the treatment is working. This could help better understand how dostarlimab contributes to the response of the disease to treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has a tumor demonstrating the presence of either-
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive dostarlimab plus CAPEOX (chemotherapy).
Biological: Dostarlimab · Drug: CAPEOX
Participants will receive CAPEOX (chemotherapy).
Drug: CAPEOX
Dostarlimab will be administered.
Also known as: GSK4057190A, TSR-042
Drug page: Xelox
CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.
Major pathological response (mPR) rate
mPR rate is defined as the proportion of participants with ≤10% residual viable tumor (RVT) value in the surgical resection sample as determined by local assessment.
Time frame: Up to approximately 18 weeks
Number of participants with adverse events (AEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs), and AEs leading to death or discontinuation of study intervention
Time frame: Up to approximately 105 weeks
Percentage of participants for whom primary tumour resection is not excluded
Time frame: Up to approximately 18 weeks
Complete pathologic response (cPR) rate
cPR rate is defined as the proportion of participants with 0% RVT value in the surgical resection sample as determined by local assessment.
Time frame: Up to approximately 18 weeks
Major pathological response excluding cPR rate
mPR rate is defined as the proportion of participants with ≤10% RVT value in the surgical resection sample as determined by local assessment. cPR rate is defined as the proportion of participants with 0% RVT value in the surgical resection sample as determined by local assessment.
Time frame: Up to approximately 18 weeks
Partial pathologic response rate
Partial pathologic response rate is defined as the proportion of participants with \>10% and ≤50% RVT value in the surgical resection sample as determined by local assessment.
Time frame: Up to approximately 18 weeks
Negligible pathologic response rate
Negligible pathologic response rate is defined as the proportion of participants with \>50% RVT value in the surgical resection sample as determined by local assessment.
Time frame: Up to approximately 18 weeks
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.
Of 136 phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dostarlimab